I-Mab - IMAB STOCK NEWS

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced its participation in several conferences in January 2022, including the 40th Annual J.P. Morgan Healthcare Conference, Morgan Stanley Virtual China New Economy Summit 2022, H.C. Wainwright Virtual BioConnect Conference, and UBS Greater China Conference 2022. Management will present and hold meetings with investors, featuring key executives including Dr. Jingwu Zang, Chairman and Acting CEO. These engagements aim to enhance visibility and foster relationships with investors.

I-Mab (Nasdaq: IMAB) announced that China's National Medical Products Administration has approved its IND submission to start a phase 2 clinical trial for enoblituzumab, combined with pembrolizumab, targeting solid tumors like non-small cell lung cancer. Enoblituzumab, a monoclonal antibody against B7-H3, showed promising anti-tumor activity in preclinical studies. The trial aims to assess the treatment's efficacy in various cancer types, leveraging preliminary data from MacroGenics that supports its potential effectiveness in recurrent or metastatic NSCLC.

I-Mab (Nasdaq: IMAB) has announced significant leadership changes aimed at accelerating its transition toward commercialization. Dr. Andrew Zhu, a prominent oncologist, has been appointed as President and board director, focusing on global R&D pipeline development. Founder Dr. Jingwu Zang will serve as Acting CEO starting January 1, 2022. The newly formed Commercialization Executive Council aims to enhance corporate partnerships and development. An investor call is scheduled for December 21, 2021, to introduce the new leadership team.

I-Mab (Nasdaq: IMAB) announced the approval from China's National Medical Products Administration for the IND submission to initiate a phase 1 clinical study for TJ-CD4B, a bispecific antibody aimed at treating solid tumors, including gastric and pancreatic cancers. This marks a significant milestone as it's the first CLDN18.2 x 4-1BB bispecific antibody in clinical trials in China. Preclinical studies have shown promising results, indicating strong immune activation without systemic toxicity. The study will complement ongoing trials in the U.S., potentially accelerating overall clinical development.

I-Mab (Nasdaq: IMAB) announced interim results from its clinical trial of lemzoparlimab, a CD47 antibody, in combination with rituximab for heavily treated patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). The study reported safety and tolerability with no need for a priming dose, and an overall response rate of 71%, with 4 complete responses among 7 evaluable patients. The ongoing study aims to expand patient enrollment for further evaluation. I-Mab continues to accelerate the clinical development of lemzoparlimab both in the U.S. and China.

I-Mab (Nasdaq: IMAB) announced an investor call scheduled for December 14, 2021, at 8:00 a.m. EST to discuss recent clinical data on lemzoparlimab combined with rituximab for treating relapsed or refractory non-Hodgkin's lymphoma. The company is focused on developing lemzoparlimab, a novel CD47 antibody designed to minimize side effects typically associated with this class of drugs. Ongoing studies in the U.S. and China aim to explore its efficacy across various malignancies, which could pave the way for future registrational trials.

I-Mab (Nasdaq: IMAB) announced the dosing of the first patient in a U.S. Phase I study of Protollin, an investigational drug for Alzheimer's disease. Conducted by Brigham and Women's Hospital, this randomized, double-blind trial assesses the safety and immune effects of Protollin on early symptomatic Alzheimer’s patients. The drug is designed to stimulate the innate immune system to combat beta amyloid plaques. Following FDA's acceptance of its IND submission in July 2021, this marks a significant milestone in developing new Alzheimer’s therapies.

I-Mab (Nasdaq: IMAB) announced its Board of Directors approved a motion for a dual listing of the company's ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited. The move is subject to market conditions, further Board approvals, and necessary regulatory clearances. I-Mab aims to enhance its global presence and facilitate capital raising through this initiative. As a clinical-stage biopharmaceutical company, I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, supported by a robust pipeline of drug candidates.

I-Mab (Nasdaq: IMAB) announced the dosing of the first two patients in the U.S. phase 2 clinical study of its CD73 antibody, uliledlimab (TJD5), combined with atezolizumab (Tecentriq®) for patients with advanced ovarian cancer and other solid tumors. The study aims to evaluate uliledlimab's therapeutic potential and biomarkers in immune-resistant cancer types. Previous phase 1 trials showed favorable safety and promising efficacy. I-Mab is concurrently advancing uliledlimab’s development in China, indicating a robust strategy for global clinical advancement.